Whole Exome Sequencing Market to Grow at 19.8% CAGR to Reach $3,812 Million by 2027 Driven by Rising Need of Molecular Diagnosis

Sequencing by synthesis is expected to drive the growth of the global whole exome sequencing market by technology segment.

Get Sample Copy of this research report at https://www.theinsightpartners.com/sample/TIPRE00005519/?OpenPR-10115

The whole exome sequencing is an emerging market consisting of the good and countable number of players, having considerable revenue in the market. Most of the companies operating in the global whole exome sequencing market offer whole exome sequencing services to the patients who are searching for a unifying diagnosis for multiple medical conditions. Exome sequencing using exome enrichment can efficiently detect coding variants across a wide range of applications, including population genetics, genetic disease and cancer studies.

The most notable market participants are Thermo Fisher Scientific Inc., Illumina, Inc., Centogene AG, F. Hoffmann-La Roche AG, Psomagen, Inc. (previuosly Macrogen Corp.), Pacific Biosciences of California, Inc., Brooks Automation, Inc. (GENEWIZ, Inc.), Bio-Rad Laboratories, Inc., Eurofins Scientific and Stratos Genomics among the others .These companies have occupied a considerable share of the market owing to their product offerings to the companies.

Market leaders are involved in organic and inorganic growth strategies in the whole exome sequencing market. For instance, the companies have maximized their growth with few organic strategies to enhance the market value and position in the market. The organic developments in the market were maximum among the development in the whole exome sequencing.
The market has experienced several organic strategies such as product launch, product approval and expansion activities that also has resulted positively for the growth of the market. The companies have also conducted few inorganic strategies such as partnership, acquisitions and agreements that has enhance the product portfolio.

The whole exome sequencing is the next generation technique which is widely preferred as substitute for the whole genome sequencing due to its advantages. Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing (WES) is available to patients who are searching for a unifying diagnosis for multiple medical conditions. Exome sequencing using exome enrichment can efficiently detect coding variants across a wide range of applications, including population genetics, genetic disease and cancer studies.

Direct Purchase a Copy of this research at https://www.theinsightpartners.com/buy/TIPRE00005519/?OpenPR-10115

Global whole exome sequencing market was segmented by product & service, technology, and application. On the basis of the product & service, the market is segmented as systems, kits and services. Services segment is further sub-segmented into sequencing services and data analysis (bioinformatics) and other services. Based on the technology, the whole exome sequencing market is segmented into sequencing by synthesis, ion semiconductor sequencing and other technologies.

On the basis of the application, the whole exome sequencing market is segmented into diagnostics, drug discovery & development, personalized medicine and others. Diagnostics segment is further sub-segmented into cancer diagnostics, monogenic (mendelian) disorders diagnostics, monogenic types of diabetes diagnostics and HIV diagnostics and other diagnostics.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

This release was published on openPR.